Use of stop-smoking medications in the United States before and after the introduction of varenicline

Addiction

Volumn 110, Issue 2, 2015, Pages 346-355

  Kasza, Karin A ^a   Cummings, K Michael ^b   Carpenter, Matthew J ^b   Cornelius, Monica E ^b   Hyland, Andrew J ^a   Fong, Geoffrey T ^c,d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF WATERLOO   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Bupropion; Cessation; Nicotine replacement therapy; Stop smoking medication; Trends; Varenicline

Indexed keywords

NICOTINE GUM; NICOTINIC AGENT; VARENICLINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CROSS-SECTIONAL STUDY; DRUG APPROVAL; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; PREVENTION AND CONTROL; PROSPECTIVE STUDY; SMOKING; SMOKING CESSATION; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CROSS-SECTIONAL STUDIES; DRUG APPROVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; PROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; SOCIOECONOMIC FACTORS; TOBACCO USE CESSATION PRODUCTS; UNITED STATES; VARENICLINE; YOUNG ADULT;

EID: 84923032316     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12778     Document Type: Article

References (28)

1. Gonzales D., Rennard S. I., Nides M., Oncken C., Azoulay S., Billing C. B. etal. Varenicline, an alpha4-beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55.
2. Cahill K., Stead L. F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008; 1: CD006103.
3. US Food and Drug Administration. NME Drug and New Biologic Approvals in 2006: Varenicline. 2006. Available at: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ucm081673.htm (accessed 21 April 2014).
4. Stead L. F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; 1: CD000146. pub3.
5. Hughes J. R., Stead L. F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD000031.
6. US Food and Drug Administration. Information for healthcare professionals: varenicline (marketed as Chantix). 2008. FDA ALERT [2/1/2008]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124818.htm (accessed 21 April 2014).
7. US Food and Drug Administration. Information for healthcare professionals: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics). 2009. FDA ALERT [7/1/2009]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm (accessed 21 April 2014).
8. Garrison G. D., Dugan S. E. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009; 31: 463-491.
9. Gibbons R. D., Mann J. J. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry 2013; 170: 1460-1467. doi: 10.1176/appi.ajp.2013.12121599.
10. Jiménez-Ruiz C., Berlin I., Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs 2009; 69: 1319-1338. doi: 10.2165/00003495-200969100-00003.
11. Prochaska J. J., Hilton J. F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344: e2856. doi: 10.1136/bmj.e2856.
12. Kotz D., Fidler J. A., West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res 2011; 13: 793-799.
13. Langley T. E., Huang Y., McNeill A., Coleman T., Szatkowski L., Lewis S. Prescribing of smoking cessation medication in England since the introduction of varenicline. Addiction 2011; 106: 1319-1324.
14. Fix B. V., Hyland A., Rivard C., McNeill A., Fong G. T., Borland R. etal. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health 2011; 8: 222-233.
15. Fong G. T., Thompson M., Hammond D., Boudreau C., Driezen P. International Tobacco Control Policy Evaluation Survey (ITC), Four Country Project, Waves 2-8 Technical Report. 2011. Available at: http://www.itcproject.org/documents/keyfindings/4cw28techreportmay2011_2_pdf (accessed 17 February 2012) (Archived by WebCite® at http://www.webcitation.org/65WmeqN1E).
16. Hammond D., Fong G. T., Thompson M. E., Driezen P. International Tobacco Control Policy Evaluation Survey (ITC), Four Country Project, Wave 1 Technical Report. 2004. Available at: http://www.itcproject.org/documents/keyfindings/technicalreports/itcw1techreportfinalpdf (accessed 17 February 2012) (Archived by WebCite® at http://www.webcitation.org/65WlnsWWy).
17. Fong G. T., Cummings K. M., Borland R., Hastings G., Hyland A. J., Giovino G. A. etal. The conceptual framework of the International Tobacco Control (ITC) Policy Evaluation Project. Tob Control 2006; 15: iii3-11.
18. Thompson M. E., Fong G. T., Hammond D., Boudreau C., Driezen P., Hyland A. etal. Methods of the International Tobacco Control (ITC) Four Country Survey. Tob Control 2006; 15: iii12-18.
19. Heatherton T. F., Kozlowski L. T., Frecker R. C., Rickert W., Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict 1989; 84: 791-800.
20. International Tobacco Control Policy Evaluation Project. 4-Country Survey Questionnaires. 2009-2011. Available at: http://www.itcproject.org/ (accessed 17 February 2012) (Archived by WebCite® at http://www.webcitation.org/65Wm59nLc).
21. Hardin J. W., Hilbe J. M. Generalized Estimating Equations. Boca Raton, FL: Chapman & Hall/CRC; 2003.
22. Liang K. Y., Zeger S. L. Longitudinal data using generalized linear models. Biometrika 1986; 73: 13-22.
23. StataCorp. Stata Statistical Software, Version 11. College Station, TX: StataCorp LP; 2009.
24. Kotz D., Brown J., West R. 'Real-world' effectiveness of smoking cessation treatments: a population study. Addiction 2013; 109: 491-499. doi:10.1111.
25. Kasza K. A., Hyland A. J., Borland R., McNeill A., Bansal-Travers M., Fix B. V. etal. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction 2013; 108: 193-202.
26. Gfroerer J., Dube S. R., King B. A., Garrett B. E., Babb S., McAfee T. Vital signs: current cigarette smoking among adults aged >18 years with mental illness-United States, 2009-2011. Morb Mortal Wkly Rep 2013; 62: 81-87.
27. International Tobacco Control (ITC) Project. February, 2014. ITC United States National Report. Findings from the Wave 1 to 8 Surveys (2002-2011). University of Waterloo, Waterloo, Ontario, Canada and Medical University of South Carolina, Charleston, South Carolina, United States.
28. Borland R., Partos T. R., Cummings K. M. Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop-smoking medications. Nicotine Tob Res 2012; 14: 1483-1487. doi: 10.1093/ntr/nts002.